MARKET NEWS

Biomerica Announces Positive Topline Results From the Endpoint Clinical Trial
Eyenovia Concludes Type A Meeting With FDA Related to MydCombi NDA Resubmission
Recce Pharmaceuticals Announces Positive Safety Data From Third Cohort of Phase 1 Clinical Trial
Kintara Therapeutics Announces Issuance of New US Patent Related to VAL-083 & MGMT Resistance: Implications for Targeting Brain Tumor Stem Cells
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial

  FEATURED EDITORIAL

 

  COMPANY PROFILE

Emergent CDMO is dedicated to helping pharma and biotech innovators bring life-saving, life-extending therapies to patients throughout the world. Our development and manufacturing facilities in North America and Europe can support preclinical to commercial production of therapeutics and vaccines. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced CDMO team is ready to serve as your trusted guide from molecule to market. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Xanadu Bio Obtains Licenses & Options to Novel Platform Technologies From Yale University to Develop Intranasal SARS CoV-2 mRNA Vaccine Booster

Xanadu Bio Obtains Licenses & Options to Novel Platform Technologies From Yale University to Develop Intranasal SARS CoV-2 mRNA Vaccine Booster

Xanadu Bio recently announced a broad exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed….

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial

Ocuphire Pharma, Inc. recently announced it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically….

Ovid Therapeutics & Healx to Enter Strategic Partnership

Ovid Therapeutics & Healx to Enter Strategic Partnership

Ovid Therapeutics and Healx recently announced Healx has secured from Ovid an exclusive option to license rights to develop and commercialize gaboxadol. Under the agreement, Healx plans to….

Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 23 – ODT/Fast Dissolve
March 2 – Transdermal/Topical Delivery